IDH1 and IDH2 Mutations in Gliomas
作者： Adam L. Cohen , Sheri L. Holmen , Howard Colman
DOI: 10.1007/S11910-013-0345-4
关键词:
摘要: Mutations in isocitrate dehydrogenase (IDH) 1 and 2, originally discovered 2008, occur the vast majority of low-grade gliomas secondary high-grade gliomas. These mutations, which early gliomagenesis, change function enzymes, causing them to produce 2-hydroxyglutarate, a possible oncometabolite, not NADPH. IDH mutations are oncogenic, although whether mechanism is through alterations hydroxylases, redox potential, cellular metabolism, or gene expression clear. The also drive increased methylation Gliomas with mutated IDH1 IDH2 have improved prognosis compared wild-type IDH. Mutated can now be detected by immunohistochemistry magnetic resonance spectroscopy. No drugs currently target IDH, this remains an area active research.
springer.com
sci-hub.se 参考文章(77)
S. Zhao, Y. Lin, W. Xu, W. Jiang, Z. Zha, P. Wang, W. Yu, Z. Li, L. Gong, Y. Peng, J. Ding, Q. Lei, K.-L. Guan, Y. Xiong, Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α Science. ,vol. 324, pp. 261- 265 ,(2009) , 10.1126/SCIENCE.1170944
Genglin Jin, Zachary J. Reitman, Ivan Spasojevic, Ines Batinic-Haberle, Jian Yang, Oleg Schmidt-Kittler, Darell D. Bigner, Hai Yan, 2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations PLoS ONE. ,vol. 6, pp. e16812- ,(2011) , 10.1371/JOURNAL.PONE.0016812
M Labussiere, A Idbaih, X-W Wang, Y Marie, B Boisselier, C Falet, S Paris, J Laffaire, C Carpentier, E Criniere, F Ducray, S El Hallani, K Mokhtari, K Hoang-Xuan, J-Y Delattre, M Sanson, None, All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 Neurology. ,vol. 74, pp. 1886- 1890 ,(2010) , 10.1212/WNL.0B013E3181E1CF3A
Shimin Zhao, Kun-Liang Guan, None, IDH1 mutant structures reveal a mechanism of dominant inhibition. Cell Research. ,vol. 20, pp. 1279- 1281 ,(2010) , 10.1038/CR.2010.160
Adrianna Ranger, Artur Szymczak, Do intracranial neoplasms differ in Ollier disease and maffucci syndrome? An in-depth analysis of the literature. Neurosurgery. ,vol. 65, pp. 1106- 1115 ,(2009) , 10.1227/01.NEU.0000356984.92242.D5
Jean-Pierre Bayley, Peter Devilee, Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree? Current Opinion in Genetics & Development. ,vol. 20, pp. 324- 329 ,(2010) , 10.1016/J.GDE.2010.02.008
Qi SongTao, Yu Lei, Gui Si, Ding YanQing, Han HuiXia, Zhang XueLin, Wu LanXiao, Yao Fei, IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma Cancer Science. ,vol. 103, pp. 269- 273 ,(2012) , 10.1111/J.1349-7006.2011.02134.X
Shakuntala H Mauzo, Michael Lee, John Petros, Stephen Hunter, Chi-Ming Chang, Hui-Kuo Shu, Anita C Bellail, Chunhai Hao, Cynthia Cohen, None, Immunohistochemical demonstration of isocitrate dehydrogenase 1 (IDH1) mutation in a small subset of prostatic carcinomas. Applied Immunohistochemistry & Molecular Morphology. ,vol. 22, pp. 284- 287 ,(2014) , 10.1097/PAI.0B013E3182649D1C
Sevin Turcan, Daniel Rohle, Anuj Goenka, Logan A. Walsh, Fang Fang, Emrullah Yilmaz, Carl Campos, Armida W. M. Fabius, Chao Lu, Patrick S. Ward, Craig B. Thompson, Andrew Kaufman, Olga Guryanova, Ross Levine, Adriana Heguy, Agnes Viale, Luc G. T. Morris, Jason T. Huse, Ingo K. Mellinghoff, Timothy A. Chan, IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature. ,vol. 483, pp. 479- 483 ,(2012) , 10.1038/NATURE10866
David Capper, Hanswalter Zentgraf, Jörg Balss, Christian Hartmann, Andreas von Deimling, Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathologica. ,vol. 118, pp. 599- 601 ,(2009) , 10.1007/S00401-009-0595-Z